Journal Article

Plasma CXCL4–DNA/RNA Complexes and Anti-CXCL4 Antibodies Modulation in an SSc Cohort under Iloprost Treatment

Ocone, Giuseppe, Pietraforte, Immacolata, Mennella, Anna, Palazzo, Raffaella, Riccieri, Valeria, Lande, Roberto, Truglia, Simona, Bisconti, Ilaria, Stefanantoni, Katia, Frasca, Loredana, Pisacreta, Alba

2024

Overview

Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular and immunity alterations and skin/internal organ fibrosis. Aberrant levels of plasma CXCL4, CXCL4–RNA/DNA complexes, type I IFN (IFN-I) and anti-CXCL4 antibodies characterize SSc. These parameters influence each other: CXCL4–self-DNA/RNA complexes are triggers of IFN-I in plasmacytoid dendritic cells (pDCs), and anti-CXCL4 autoantibodies amplify this effect. Here, we assess the modulation over time of plasma CXCL4 and the related parameters of CXCL4–DNA/RNA complexes, anti-CXCL4 antibodies, IFN-α and TNF-α in an SSc cohort under the synthetic analogue of prostacyclin PGI2 (iloprost) treatment to address contribution of these parameters to pathogenesis and their role as biomarkers. Methods: We analyzed immunological parameters at baseline (T0) and after 3 (T3) and 6 (T6) months in 30 SSc patients. Responders were the patients that lowered their disease activity parameters after six months of treatment. Results: Anti-CXCL4 autoantibodies correlated with both IFN-α and TNF-α levels in SSc plasma. Responders significantly down-regulated serum IFN-α. In seven patients with a shorter disease duration, improvement coincides with a decrease in plasma IFN-α, CXCL4 and TNF-α. Iloprost efficiently blocks pDCs IFN-α production induced by CXCL4–DNA/RNA complexes in vitro. Conclusions: The data suggest a possible role of iloprost as a disease-modifying drug, mainly accompanied by down-regulation of plasma IFN-I levels. Since CXCL4, IFN-I and TNF-α down-modulation was evident and significant in improving SSc patients with a shorter disease duration, these results warrant future investigations on the early use of iloprost to slow SSc progression.

• Publisher: MDPI AG,MDPI
• Subject: Analysis / Angiogenesis / Antibodies / Autoantibodies / Autoimmunity / Blood platelets / Care and treatment / Chemokines / CXCL4 / Dosage and administration / Drugs / Health aspects / Iloprost / Inflammation / Medical physics. Medical radiology. Nuclear medicine / Medicine (General) / Plasma / plasmacytoid dendritic cells (pDCs) / R5-920 / R895-920 / Scleroderma / Scleroderma (Disease) / Systemic scleroderma / systemic sclerosis (SSc) / systemic sclerosis (SSc); iloprost; type I interferon (IFN-I); CXCL4; plasmacytoid dendritic cells (pDCs) / type I interferon (IFN-I)